NOVARTIS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 89.81 CHF | -0.63% |
|
-3.71% | +5.82% |
| Dec. 06 | Swiss Market Index Ends Week Little Changed; Holcim Shares Down | MT |
| Dec. 06 | Novartis Reports 'Positive' Results From Phase 3 Study of Potential Blood Disorder Therapy | MT |
Main competitors
| Revenues ($) (Y-1) | Net margin (Y-1) | Operating Margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Debt/EBITDA) (Y-1) | ||
|---|---|---|---|---|---|---|---|
| 45.44B | +32.69% | +36.03% | +25.37% | +12.37% | 0.67x | ||
| 34.12B | +15.36% | +20.68% | +48.93% | +9.23% | 2.6x | ||
| 32.92B | +36.03% | +44.16% | +88.07% | +30.12% | -0.03x | ||
| 85.16B | +41.28% | +32.25% | +34.91% | +14.32% | 0.21x | ||
| 54.32B | +8.95% | +45.64% | +143.18% | +14.46% | 1.82x | ||
| 60.12B | +0.61% | +10.33% | +9.18% | +3.56% | 2.77x | ||
| 66.93B | +19.58% | +32.77% | +45.73% | +16.71% | 0.85x | ||
| 45.81B | +13.01% | +31.73% | +29.77% | +11.48% | 1.66x | ||
| 28.19B | +23.83% | +47.53% | +202.85% | +12.37% | 3.07x | ||
| 58.5B | +3.62% | +15.90% | +11.37% | +4.96% | 3.8x | ||
| 45.51B | +12.54% | +29.42% | +13.65% | +4.27% | 0.55x | ||
| 45.01B | +17.83% | +37.30% | +51.57% | +8.36% | 1.55x | ||
| 27.12B | +20.89% | +38.66% | +38.46% | +13.49% | 1.34x | ||
| 7.41B | +29.29% | +39.52% | +21.30% | +23.34% | -1.57x | ||
| 38.66B | +16.25% | +28.97% | +52.48% | +10.55% | 1.29x | ||
| 10.68B | +12.53% | +13.21% | +12.80% | +7.95% | -2.01x | ||
| 28.44B | +3.38% | +5.02% | +2.10% | +0.36% | 4.66x | ||
| 3.14B | +18.85% | +21.52% | +10.99% | +9.99% | -3.66x | ||
| 14.41B | +9.28% | +22.55% | +6.37% | +3.05% | 3.01x | ||
| Average | 38.52B | +17.67% | +29.11% | +44.69% | +11.10% | 1.19x | |
| Weighted average by Cap. | 45.28B | +20.12% | +30.79% | +55.78% | +13.23% | 1.42x |
- Stock Market
- Equities
- NOVN Stock
- Sector Novartis AG
- Financial comparisons